FlandersBio and Flemish Life Science Cluster Strategy. State of the Union, May 25th 2016

Transcription

1 FlandersBio and Flemish Life Science Cluster Strategy State of the Union, May 25th 2016

2 FlandersBio has been working to answer 2 major questions as they plan for the future 1 What is our ambition as a life science cluster? Our Cluster strategy: Why companies should be a cluster member 2 How can FlandersBio support and grow the cluster over the next 5 years? Our FlandersBio 2.0 Strategy: How FlandersBio needs to change to fulfil the cluster strategy

3 FlandersBio 2.0 s cluster development strategy supports the future converging Life Science business model Life science business model development: Focus of FlandersBio s 2.0 cluster development strategy: healthy living HEALTH Life science - Drug Value Chain - Long product life cycle - Heavy funding requirements - Mature clusters FOOD, AGRI, INDUSTRIAL & ENERGY Life science - Industrial products value chain - Shorter product life cycle - Not heavy funding requirements - Emerging clusters NEW TECHNOLOGY - Genomics - Proteomics - Metabolomics - New sources of energy - New food technologies Health Nutrition Energy Environment NEW BUSINESS MODEL Longer and more complex value chains Complex and gray regulations Environmental constraints New alternative energy sources Ethical constraints Impact on customer habits Long product life cycle Risky funding needs Development over time The new life science business model is based on a convergence of technologies and life science areas, resulting in longer and more complex value chains and more risky funding needs.

4 Our ambition is to be a cluster of choice through a framework of 7 initiatives Cluster Strategy FlandersBio Cluster Framework FlandersBio aims to be the cluster of choice by driving growth and adding value to cluster members while being self-sustaining and differentiated Excellence in Access to Science & Technology Innovation Creating winners / Reputation Building Access to Finance Industry-ready Talent & Capabilities Testing region in life sciences 4 Cross-Sector Collaboration The Flanders Life Science Cluster wants to be amongst the top clusters in the world Together these initiatives will support cluster members and stakeholders across the value chain, from research to commercialisation

5 The FlandersBio Cluster Framework Cluster Strategy Excellence in Science & Innovation Access to Technology Testing region in Life Sciences Better access to top science across the value chain, increasing the ability to create more high-value assets Reduce hurdles for early research collaboration with universities Attract more Top Scientists Closer collaboration other science clusters Better access to life science technologies and solutions through: Collaborations between companies Local knowledge institutions both in life science and other sectors Creating winners / Reputation Building Build the reputation of Flanders both locally and internationally and create winners Access to Finance Consolidate our position as the preferred region to pilot life sciences product and process innovation : Fast execution of innovative evidence based trials through coordinated capabilities across all stakeholders Optimal environment to pilot test and market new processes and products Cross-Sector Collaboration Collaborate with an ecosystem of external stakeholders 7 Activate better finance opportunities, including: Funding/financing for both private and publicly quoted companies Support for EU-government funding applications Industry-ready Talent & Capabilities Train the right talent and capabilities to support the FlandersBio cluster and its members

6 The 2.0 Strategy outlines how FlandersBio will support the cluster goal of becoming one of the Top clusters 2.0 Strategy FlandersBio as a cluster organisation: Main activities and focus for FlandersBio Where is FlandersBio now, and where will we need to go Timeline / roadmap

7 FlandersBio will focus on players in early R&D and collaborate with others in the outside areas 2.0 Strategy Value Chain: Innovation research POC research POC development Clinical / field trials Market access / product placement Mature markets FlandersBio 2.0 should focus on these areas: There is currently little support for these players by other associations or organisations This will help FlandersBio to differentiate itself from others in the ecosystem FlandersBio will collaborate across other parts of the value chain

8 The 2.0 Strategy will gradually add new activities over time 2.0 Strategy 3 1 Optimize existing activities towards focus areas and focus on talent development 2 Become a deep Life Science SME expert hub and act as a service broker and virtual accelerator Expertise FlandersBio 2.0 Act as a voice for the sector through active building of policy proposals and attractive engagement forums for stakeholders Lobbying Expertise Services Services Services FlandersBio 1.0 Training Training Training Advocacy Advocacy Advocacy Advocacy Networking Networking Networking Networking Timeline Today Short-term Horizon 1 ( ) Mid-term Horizon 2 ( ) Long-term Horizon 3 (>2020)

9 The FlandersBio 2.0 action plan Cluster initiatives: Excellence in Science & Innovation Access to Technology Testing region in Life Sciences Objectives: To maintain and improve top science across the value chain, increasing the ability to create more high-value assets Build on recognized and specific strengths of the Flemish region. Reduce specific local hurdles towards more game changing R&D initiatives Focus on fundamental drivers of cluster success To improve access to life science technologies and solutions through: Collaborations between companies Local knowledge institutions both in life science and other sectors To be the preferred region to pilot life sciences product and process innovation Fast execution of innovative evidence based trials through coordinated capabilities across all stakeholders Optimal environment to pilot test and market new processes and products Actions: 1 To map successful top science programs in Belgium and other clusters and to establish an interactive internal science and innovation knowledge base of expertise and facilities present among all stakeholders Implement the re-branding of the cluster 2 Facilitate the creation of synergy generating satellite platforms as interphases between academia and industry (FlandersVaccine, Precision Medicine, TTO etalage) 3 Position the region as the preferred evidence-based testing region in EU and work with partners on lobbying (early discussion on testing regimes, faster access to market, transparent processes)

10 The FlandersBio 2.0 action plan Cluster initiative: 4 Actions: Cross-Sector Collaboration Objective: To collaborate with an ecosystem of external stakeholders 4 Create Cross sector Collaboration Platforms: XKet4Health Health Cluster EU cluster collaboration with selected clusters

11 The FlandersBio 2.0 action plan 5 Cluster initiatives: Creating winners / Reputation Building Objectives: To build the reputation of Flanders both locally and internationally and to create winners 6 7 Access to Finance Industry-ready Talent & Capabilities To optimize finance opportunities, including: Funding/financing for both private and publicly quoted companies Support for EU-government funding applications To orient and train the right talent and capabilities to support the FlandersBio cluster and its members Actions: 5 Establish a Funding Platform Permanent update on subsidy programs (local and EU) Overview of local and international investors Bioequity to Flanders 6 Competence analysis and creation of Life Sciences & Health Academy 7 Perform analysis and define best practices & recommendations to create winners

12 FlandersBio 2.0 value add for it s members Intensified interaction and collaboration Increased support & service Better access to technology and expertise (incl. training) Page 12